Stifel raised the firm’s price target on Exelixis (EXEL) to $38 from $36 and keeps a Hold rating on the shares. Cabometyx sales of $511M “easily beat” the firm’s and consensus estimates, notes the analyst, whose updated model mostly reflects higher FY25 estimates and the NET launch, which the firm says should prove a tailwind to FY25 top-line growth and command an additional guidance raise above the $100M announced already.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis Hold Rating: Strong Performance and Promising Pipeline Balanced by Fair Valuation
- Exelixis price target raised to $46 from $41 at Citizens JMP
- Exelixis: Strong Financial Performance and Market Position Justify Buy Rating
- Exelixis Reports Strong Q1 2025 Financial Performance
- Exelixis: Strong Financial Performance and Promising Pipeline Drive Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue